2 Things About AbbVie That Investors Are Ignoring

2 Things About AbbVie That Investors Are Ignoring

Source: 
Motley Fool
snippet: 
  • AbbVie’s sales of two key immunology drugs missed some analysts' estimates -- but plenty of signs point to long-term growth.
  • The company also is excelling in two other growth markets.